Company Description
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands.
It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer.
It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.
The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024.
Renovaro Inc. is headquartered in Los Angeles, California.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | David Weinstein |
Contact Details
Address: 2080 Century Park East, Suite 906 Los Angeles, California 90067 United States | |
| Phone | 305 918 1980 |
| Website | renovarobio.com |
Stock Details
| Ticker Symbol | RENB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001527728 |
| CUSIP Number | 29350E104 |
| ISIN Number | US29350E1047 |
| Employer ID | 45-2259340 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David H. Weinstein | Chief Executive Officer and Director |
| Simon Tarsh | Interim Chief Financial Officer |
| Dr. Francois Binette M.Sc., Ph.D. | Chief Operating Officer and Executive Vice President for Research and Development |
| Dr. Serhat Gümrükcü | Co-Founder and Inventor |
| Greg Duczynski Ph.D. | Senior Vice President for Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 19, 2025 | 10-Q | Quarterly Report |
| Feb 19, 2025 | 10-Q/A | [Amend] Quarterly report |
| Feb 19, 2025 | 10-K/A | [Amend] Annual report |
| Feb 19, 2025 | 10-Q/A | [Amend] Quarterly report |
| Feb 19, 2025 | 8-K | Current Report |
| Feb 18, 2025 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Feb 10, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |
| Jan 7, 2025 | 8-K | Current Report |
| Jan 6, 2025 | 8-K | Current Report |